form12b25.htm
 
  U.S. SECURITIES AND EXCHANGE COMMISSION  
 
WASHINGTON, D.C. 20549
  
     
 
FORM 12b-25
Commission File Number
     
814-00717
 
NOTIFICATION OF LATE FILING
  
     
CUSIP Number
     
 910203 10 8
 

 
(Check One):
 x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form N-SAR
           
 
For Period Ended: December 31, 2010

o Transition Report on Form 10-K
o Transition Report on Form 20-F
o Transition Report on Form 11-K
o Transition Report on Form 10-Q
o Transition Report on Form N-SAR
 
For the Transition Period Ended:
 
 
Read Attached Instruction Sheet Before Preparing Form.  Please Print or Type.
Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  N/A

Part I - Registrant Information
 
United Health Products, Inc.
      
Full Name of Registrant:
      
       
       
Former Name if Applicable:  
      
       
120 Wall Street, Suite 2401,      
Address of Principal Executive Office (Street and Number)
      
       
New York, NY 10005
      
(City, State and Zip Code)
      
 
 
1
 
 
Part II - Rules 12b-25(b) and (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
  x (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense.
  x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant's statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

PART III - Narrative
 
State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof could not be filed within the prescribed period.
 
The process of compiling and disseminating the information required to be included in the Form 10K for the year ended December 31, 2010, as well as the completion of the required audit of the Company’s financial information, could not be completed without incurring undue hardship and expense.  The registrant will file the annual report on or before April 15, 2010.
 
Part IV - Other Information

(1)  Name and telephone number of person to contact in regard to this notification:
 
W. Raymond Felton
c/o Greenbaum Rowe Smith & Davis LLP      
  
(732)
  
476-2670
  (Name)
  
 (Area Code)
  
(Telephone No.)
         
 
(2)  Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
x Yes   o No
 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
o Yes   x No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
2
 
 
United Health Products, Inc.
(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
                            
Date: April 1, 2011   By:
 /s/ Jan E. Chason
       
Jan E. Chason
       
Chief Financial Officer
                               
INSTRUCTION:  The form may be signed by an executive officer or by any other duly authorized representative.  The name and title of the person signing the form shall be typed or printed beneath the signature.  If the statement is signed on behalf of the Registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the Registrant shall be filed with the form.
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3